<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04875416</url>
  </required_header>
  <id_info>
    <org_study_id>20200888</org_study_id>
    <secondary_id>U54NS092091</secondary_id>
    <nct_id>NCT04875416</nct_id>
  </id_info>
  <brief_title>Phenotype, Genotype and Biomarkers 2</brief_title>
  <acronym>PGB2</acronym>
  <official_title>Phenotype, Genotype and Biomarkers 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn more about amyotrophic lateral sclerosis (ALS) and&#xD;
      other related neurodegenerative diseases, including frontotemporal dementia (FTD), primary&#xD;
      lateral sclerosis (PLS), hereditary spastic paraplegia (HSP), progressive muscular atrophy&#xD;
      (PMA) and multisystem proteinopathy (MSP). More precisely, the investigator wants to identify&#xD;
      the links that exist between the disease phenotype (phenotype refers to observable signs and&#xD;
      symptoms) and the disease genotype (genotype refers to your genetic information). The&#xD;
      investigator also wants to identify biomarkers of ALS and related diseases.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of change in revised ALS functional rating scale (ALSFRS-R)</measure>
    <time_frame>48 months</time_frame>
    <description>Prepare motor outcome measures for clinical trials in sub-populations of patients with ALS or a related disorder who have identifiable genetic causes of disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rates of change in Slow vital capacity (SVC)</measure>
    <time_frame>48 months</time_frame>
    <description>Prepare motor outcome measures for clinical trials in sub-populations of patients with ALS or a related disorder who have identifiable genetic causes of disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rates of change in Spastic paraplegia rating scale (SPRS)</measure>
    <time_frame>48 months</time_frame>
    <description>Prepare cognitive and behavioral outcome measures for clinical trials in sub-populations of patients with ALS or a related disorder who have identifiable genetic causes of disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rates of change in Edinburgh Cognitive and Behavioral ALS Screen (ECAS)</measure>
    <time_frame>48 months</time_frame>
    <description>Prepare cognitive and behavioral outcome measures for clinical trials in sub-populations of patients with ALS or a related disorder who have identifiable genetic causes of disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ALS Health Index (ALS-HI)</measure>
    <time_frame>48 months</time_frame>
    <description>Validate the ALS Health Index (ALS-HI), a novel patient reported outcome (PRO) measure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum</measure>
    <time_frame>48 months</time_frame>
    <description>Determine the diagnostic utility of serum neurofilament concentrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cerebrospinal Fluid (CSF)</measure>
    <time_frame>48 months</time_frame>
    <description>Determine the diagnostic utility of CSF neurofilament concentrations</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Hereditary Spastic Paraplegia</condition>
  <condition>Primary Lateral Sclerosis</condition>
  <condition>Progressive Muscular Atrophy</condition>
  <condition>Frontotemporal Dementia</condition>
  <arm_group>
    <arm_group_label>Primary participants</arm_group_label>
    <description>Patients that have or are suspected to have ALS or a related neurodegenerative disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Secondary Participants</arm_group_label>
    <description>Family members of primary participants enrolled in the study</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, Urine and CSF&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Primary participants - patients that have or are suspected to have ALS or a related&#xD;
        disease.&#xD;
&#xD;
        Secondary participants - family members of primary participants enrolled in the study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for affected individuals (primary participants) include:&#xD;
&#xD;
          -  Clinical diagnosis or suspicion of ALS or a related disorder, including, but not&#xD;
             limited to, ALS-FTD, PLS, HSP, FTD, Multisystem Proteinopathy (MSP) and PMA.&#xD;
&#xD;
          -  Subject is able and willing to comply with study procedures&#xD;
&#xD;
        Exclusion Criteria for affected individuals (primary participants) include:&#xD;
&#xD;
          -  Subjects with a condition or who are in a situation which, in the PI's opinion, could&#xD;
             confound the study finding or may interfere significantly with the individual's&#xD;
             participation and compliance with the study protocol -- including but not limited to&#xD;
             neurological, psychological and/or medical conditions&#xD;
&#xD;
        Inclusion criteria for biological family members (secondary participants) include:&#xD;
&#xD;
          -  Family member of an enrolled affected primary participant&#xD;
&#xD;
        Exclusion Criteria for biological family members (secondary participants) include:&#xD;
&#xD;
          -  Subjects with a condition or who are in a situation which, in the PI's opinion, could&#xD;
             confound the study finding or may interfere significantly with the individual's&#xD;
             participation and compliance with the study protocol -- including but not limited to&#xD;
             neurological, psychological and/or medical conditions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Benatar, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Benatar, MD, PhD</last_name>
    <phone>1-844-837-1031</phone>
    <email>projectcreate@miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Hernandez</last_name>
      <phone>305-243-2345</phone>
      <email>jph93@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Benatar, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Collin Gerringer</last_name>
      <phone>913-748-5701</phone>
      <email>cgerringer@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Statland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luis Rosario</last_name>
      <phone>215-898-3081</phone>
      <email>luis.rosario@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Corey McMillan, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cape Town</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeannine Heckmann, MD</last_name>
      <phone>+27 (021) 404-3198</phone>
      <email>jeanine.heckmann@uct.ac.za</email>
    </contact>
    <investigator>
      <last_name>Jeannine Heckmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 14, 2021</study_first_submitted>
  <study_first_submitted_qc>April 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2021</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Michael Benatar</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>PLS</keyword>
  <keyword>PMA</keyword>
  <keyword>HSP</keyword>
  <keyword>FTD</keyword>
  <keyword>MSP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Paraplegia</mesh_term>
    <mesh_term>Spastic Paraplegia, Hereditary</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

